Physician

Andrew V Grainger, MD

According to 2025 Medicare claims, Andrew Grainger, MD (NPI: 1912903386) practices hematology/oncology in the Columbus, OH market, with the plurality of this provider's patient population coming from Franklin, OH. This provider's primary affiliated billing organization is COLUMBUS ONCOLOGY ASSOCIATES INC (NPI: 1790875656; TIN: 311211874) and primary practice location at 43214-4359.

Grainger's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 504 traditional Medicare patients, billed 102,044 HCPCS/CPT codes, and received $1,316,400 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,484 prescription claims across 204 beneficiaries totaling $4,908,859 in drug costs, led by Calquence (Acalabrutinib Maleate). 2023 DME data shows 11 claims. Open Payments data shows 3 records totaling $112. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,100,721 to $4,908,859. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	367	93,415	$1,406,288
2016	437	106,184	$1,521,951
2017	445	127,451	$1,531,067
2018	452	92,977	$1,334,441
2019	434	118,585	$1,703,132
2020	387	91,397	$1,471,925
2021	465	114,590	$1,585,391
2022	516	101,873	$1,621,789
2023	498	110,578	$1,559,980
2024	504	102,044	$1,316,400

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	171	1,210	$1,100,721
2016	179	1,297	$1,474,032
2017	187	1,194	$1,222,897
2018	187	1,348	$2,071,539
2019	182	1,227	$2,513,104
2020	167	1,051	$2,370,558
2021	181	1,137	$3,627,151
2022	179	1,206	$4,202,212
2023	204	1,245	$3,801,092
2024	204	1,484	$4,908,859

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	85	$5,408
2016	N/R	161	$58,122
2017	N/R	153	$42,787
2018	N/R	110	$16,611
2019	N/R	103	$9,874
2020	N/R	41	$3,859
2021	N/R	54	$4,328
2022	N/R	N/R	N/R
2023	N/R	11	$2,600
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	65	136	$130
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	234	574	$85
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	164	198	$59
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	59	156	$42
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	331	677	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Calquence	Acalabrutinib Maleate	78	2,340	$1,196,598
Imbruvica	Ibrutinib	65	1,820	$1,074,166
Revlimid	Lenalidomide	53	1,421	$893,538
Brukinsa	Zanubrutinib	22	660	$317,538
Lenalidomide	Lenalidomide	21	581	$296,949

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$112	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	2	$9,000	Cornerstone Specialty Network LLC

Explore More Providers

FAQ

What Medicare data is available for Andrew V. Grainger, MD?

Tedicare shows public-source Medicare data for Andrew V. Grainger, MD (NPI 1912903386), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Andrew V. Grainger, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Andrew V. Grainger, MD?

Andrew V. Grainger, MD is linked to COLUMBUS ONCOLOGY ASSOCIATES INC (billing NPI 1790875656) in the available physician profile data.

Does Andrew V. Grainger, MD have Open Payments data?

Andrew V. Grainger, MD has 3 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.